Research Analysts’ Recent Ratings Changes for Johnson & Johnson (JNJ)

Johnson & Johnson (NYSE: JNJ) has recently received a number of price target changes and ratings updates:

• 1/9/2026 – Johnson & Johnson had its price target raised by analysts at Sanford C. Bernstein from $193.00 to $208.00. They now have a “market perform” rating on the stock.
• 1/5/2026 – Johnson & Johnson had its “buy” rating reaffirmed by analysts at UBS Group AG.
• 1/5/2026 – Johnson & Johnson had its price target raised by analysts at Wolfe Research from $225.00 to $240.00. They now have an “outperform” rating on the stock.
• 12/30/2025 – Johnson & Johnson had its price target raised by analysts at Barclays PLC from $197.00 to $217.00. They now have an “equal weight” rating on the stock.
• 12/18/2025 – Johnson & Johnson had its price target raised by analysts at The Goldman Sachs Group, Inc. from $213.00 to $240.00. They now have a “buy” rating on the stock.
• 12/17/2025 – Johnson & Johnson was given a new $240.00 price target on by analysts at Royal Bank Of Canada.
• 12/15/2025 – Johnson & Johnson had its price target raised by analysts at Bank of America Corporation from $204.00 to $220.00. They now have a “neutral” rating on the stock.
• 12/12/2025 – Johnson & Johnson had its price target raised by analysts at Morgan Stanley from $190.00 to $197.00. They now have an “equal weight” rating on the stock.
• 12/12/2025 – Johnson & Johnson had its price target raised by analysts at Wells Fargo & Company from $212.00 to $230.00. They now have an “overweight” rating on the stock.
• 12/11/2025 – Johnson & Johnson had its “outperform” rating reaffirmed by analysts at BMO Capital Markets.
• 12/11/2025 – Johnson & Johnson had its price target raised by analysts at Royal Bank Of Canada from $209.00 to $230.00. They now have an “outperform” rating on the stock.
• 12/11/2025 – Johnson & Johnson had its price target raised by analysts at Citigroup Inc. from $215.00 to $232.00. They now have a “buy” rating on the stock.
• 12/10/2025 – Johnson & Johnson had its “buy” rating reaffirmed by analysts at HSBC Holdings plc. They now have a $240.00 price target on the stock.
• 12/5/2025 – Johnson & Johnson had its price target raised by analysts at Guggenheim from $206.00 to $227.00. They now have a “buy” rating on the stock.
• 12/2/2025 – Johnson & Johnson had its price target raised by analysts at Barclays PLC from $176.00 to $197.00. They now have an “equal weight” rating on the stock.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Tuesday, February 24th will be given a dividend of $1.30 per share. The ex-dividend date of this dividend is Tuesday, February 24th. This represents a $5.20 dividend on an annualized basis and a yield of 2.4%. Johnson & Johnson’s payout ratio is 50.19%.

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.